Skip to main content
Erschienen in: International Journal of Clinical Oncology 12/2020

31.08.2020 | Original Article

Effectiveness of repeat surgery for recurrence after primary hepatectomy in patients with intrahepatic cholangiocarcinoma

verfasst von: Kazunori Tokuda, Yuji Morine, Yu Saito, Shinichiro Yamada, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Tetsuya Ikemoto, Satoru Imura, Mitsuo Shimada

Erschienen in: International Journal of Clinical Oncology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Intrahepatic cholangiocarcinoma (IHCC) has a poor prognosis, and surgery remains the only effective treatment. However, tumor recurrence after primary hepatectomy is common. We examined the significance of repeat surgery for IHCC.

Methods

We collected data for all patients with IHCC between 1992 and 2018 (n = 67) in our database. Fifty-three (79.1%) of all 67 patients experienced recurrence after primary hepatectomy and we analyzed data for those 53 recurrent patients. We divided recurrent patients into a repeat surgery group (n = 9), chemotherapy group (n = 19), and best supportive care group (n = 25). We analyzed differences in patients’ clinicopathological factors, including prognosis, between the three groups.

Results

The IHCC recurrence rate after hepatectomy in our institution was 79.1%. Of the 53 patients with recurrence, nine underwent repeat surgery (17.0%). The characteristics of the patients undergoing repeat surgery was lower stage at primary hepatectomy. Recurrence sites in the repeat surgery group were liver (n = 6), lung (n = 2), and adrenal gland (n = 1), as a single nodule. The period between primary hepatectomy and recurrence was comparatively longer in the repeat surgery group, at 1.8 years. The prognosis in patients undergoing repeat surgery was significantly better compared with the other groups. Not undergoing repeat surgery (hazard ratio: 5.506; p = 0.0077) and positive lymph node metastasis (hazard ratio: 2.207; p = 0.0242) were independent poor prognostic factors.

Conclusions

Repeat surgery should be considered in patients with IHCC with a single recurrence site and negative lymph node metastasis at primary surgery and at least more than 6 months of disease-free period after primary surgery.
Literatur
1.
Zurück zum Zitat Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289CrossRef Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289CrossRef
2.
Zurück zum Zitat Yamada M, Arimoto A, Touoda Y et al (2019) Long-term survival after surgical resection for recurrent hepatic and pulmonary metastases of intrahepatic cholangiocarcinoma: a case report. Surg Case Rep 5:135CrossRef Yamada M, Arimoto A, Touoda Y et al (2019) Long-term survival after surgical resection for recurrent hepatic and pulmonary metastases of intrahepatic cholangiocarcinoma: a case report. Surg Case Rep 5:135CrossRef
3.
Zurück zum Zitat Hyder O, Hatzaras I, Sotiropoulos GC et al (2013) Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 153:811–818CrossRef Hyder O, Hatzaras I, Sotiropoulos GC et al (2013) Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 153:811–818CrossRef
4.
Zurück zum Zitat Mavros MN, Economopoulos KP, Alexiou VG et al (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149:565–574CrossRef Mavros MN, Economopoulos KP, Alexiou VG et al (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 149:565–574CrossRef
5.
Zurück zum Zitat Chan K-M, Tsai C-Y, Yeh C-N et al (2018) Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence. BMC Gastroenterol 18:180CrossRef Chan K-M, Tsai C-Y, Yeh C-N et al (2018) Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence. BMC Gastroenterol 18:180CrossRef
6.
Zurück zum Zitat Yamashita Y-I, Shirabe K, Beppu T et al (2017) Surgical management of recurrent intrahepatic cholangiocarcinoma: predictors, adjuvant chemotherapy, and surgical therapy for recurrence: a multi-institutional study by the Kyushu Study Group of Liver Surgery. Ann Gastroenterol Surg 1:136–142CrossRef Yamashita Y-I, Shirabe K, Beppu T et al (2017) Surgical management of recurrent intrahepatic cholangiocarcinoma: predictors, adjuvant chemotherapy, and surgical therapy for recurrence: a multi-institutional study by the Kyushu Study Group of Liver Surgery. Ann Gastroenterol Surg 1:136–142CrossRef
7.
Zurück zum Zitat Morine Y, Shimada M, Imura S et al (2009) Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma. Hepatogastroenterology 56:307–312PubMed Morine Y, Shimada M, Imura S et al (2009) Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma. Hepatogastroenterology 56:307–312PubMed
8.
Zurück zum Zitat Souche R, Addeo P, Oussoultzoglou E et al (2016) First and repeat liver resection for primary and recurrent intrahepatic cholangiocarcinoma. Am J Surg 212:221–229CrossRef Souche R, Addeo P, Oussoultzoglou E et al (2016) First and repeat liver resection for primary and recurrent intrahepatic cholangiocarcinoma. Am J Surg 212:221–229CrossRef
9.
Zurück zum Zitat Si A, Li J, Xing X et al (2017) Effectiveness of repeat hepatic resection for patients with recurrent intrahepatic cholangiocarcinoma: factors associated with long-term outcomes. Surgery 161:897–908CrossRef Si A, Li J, Xing X et al (2017) Effectiveness of repeat hepatic resection for patients with recurrent intrahepatic cholangiocarcinoma: factors associated with long-term outcomes. Surgery 161:897–908CrossRef
10.
Zurück zum Zitat Park HM, Yun SP, Lee EC et al (2016) Outcomes for patients with recurrent intrahepatic cholangiocarcinoma after surgery. Ann Surg Oncol 23:4392–4400CrossRef Park HM, Yun SP, Lee EC et al (2016) Outcomes for patients with recurrent intrahepatic cholangiocarcinoma after surgery. Ann Surg Oncol 23:4392–4400CrossRef
11.
Zurück zum Zitat Spolverato G, Kim Y, Alexandrescu S et al (2016) Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol 23:235–243CrossRef Spolverato G, Kim Y, Alexandrescu S et al (2016) Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol 23:235–243CrossRef
12.
Zurück zum Zitat Zhang SJ, Hu P, Wang N et al (2013) Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 20:3596–3602CrossRef Zhang SJ, Hu P, Wang N et al (2013) Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 20:3596–3602CrossRef
13.
Zurück zum Zitat Liver cancer study group of Japan (2015) General rules for the clinical and pathological study of primary liver cancer. Jpn Digestive Dis. 33(6):765–770CrossRef Liver cancer study group of Japan (2015) General rules for the clinical and pathological study of primary liver cancer. Jpn Digestive Dis. 33(6):765–770CrossRef
14.
Zurück zum Zitat Morise Z, Sugioka A, Tokoro T et al (2010) Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol 2:58–64CrossRef Morise Z, Sugioka A, Tokoro T et al (2010) Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol 2:58–64CrossRef
15.
Zurück zum Zitat De Jong MC, Nathan H, Sotiropoulos GC et al (2011) Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 29:3140–3145CrossRef De Jong MC, Nathan H, Sotiropoulos GC et al (2011) Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 29:3140–3145CrossRef
16.
Zurück zum Zitat Ohtsuka M, Ito H, Kimura F et al (2003) Extended hepatic resection and outcomes in intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 10:259–264CrossRef Ohtsuka M, Ito H, Kimura F et al (2003) Extended hepatic resection and outcomes in intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 10:259–264CrossRef
17.
Zurück zum Zitat Uenishi T, Yamazaki O, Horii KT et al (2006) A long-term survivor of intrahepatic cholangiocarcinoma with paraaortic lymph node metastasis. J Gastroenterol 41:391–392CrossRef Uenishi T, Yamazaki O, Horii KT et al (2006) A long-term survivor of intrahepatic cholangiocarcinoma with paraaortic lymph node metastasis. J Gastroenterol 41:391–392CrossRef
18.
Zurück zum Zitat Higuchi R, Yamamoto M, Hatori T et al (2006) Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case. Surg Today 36:559–562CrossRef Higuchi R, Yamamoto M, Hatori T et al (2006) Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case. Surg Today 36:559–562CrossRef
19.
Zurück zum Zitat Morine Y, Shimada M (2015) The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics. J Gastroenterol 50:913–927CrossRef Morine Y, Shimada M (2015) The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics. J Gastroenterol 50:913–927CrossRef
20.
Zurück zum Zitat Morine Y, Shimada M, Imura S et al (2012) Clinical impact of lymph node dissection in surgery for peripheral-type intrahepatic cholangiocarcinoma. Surg Today 42:147–151CrossRef Morine Y, Shimada M, Imura S et al (2012) Clinical impact of lymph node dissection in surgery for peripheral-type intrahepatic cholangiocarcinoma. Surg Today 42:147–151CrossRef
21.
Zurück zum Zitat Ercolani G, Vetrone G, Grazi GL et al (2010) Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg 252:107–114CrossRef Ercolani G, Vetrone G, Grazi GL et al (2010) Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg 252:107–114CrossRef
22.
Zurück zum Zitat Yang J, Yan LN (2008) Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol 14:6289–6297CrossRef Yang J, Yan LN (2008) Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol 14:6289–6297CrossRef
23.
Zurück zum Zitat Kitamura K, Hatano E, Higashi T et al (2011) Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer. J Hepatobiliary Pancreat Sci 18:39–46CrossRef Kitamura K, Hatano E, Higashi T et al (2011) Prognostic value of 18 F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer. J Hepatobiliary Pancreat Sci 18:39–46CrossRef
24.
Zurück zum Zitat Yamamoto M, Takasaki K, Otsubo T et al (2001) Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 8:154–157CrossRef Yamamoto M, Takasaki K, Otsubo T et al (2001) Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 8:154–157CrossRef
25.
Zurück zum Zitat Saiura A, Yamamoto J, Kokudo N et al (2011) Intrahepatic cholangiocarcinoma: analysis of 44 consecutive resected cases including 5 cases with repeat resections. Am J Surg 201:203–208CrossRef Saiura A, Yamamoto J, Kokudo N et al (2011) Intrahepatic cholangiocarcinoma: analysis of 44 consecutive resected cases including 5 cases with repeat resections. Am J Surg 201:203–208CrossRef
26.
Zurück zum Zitat Kitano Y, Yamashita Y, Nakagawa S et al (2020) Effectiveness of surgery for recurrent cholangiocarcinoma: a single center experience and brief literature review. Am J Surg 219:175–180CrossRef Kitano Y, Yamashita Y, Nakagawa S et al (2020) Effectiveness of surgery for recurrent cholangiocarcinoma: a single center experience and brief literature review. Am J Surg 219:175–180CrossRef
Metadaten
Titel
Effectiveness of repeat surgery for recurrence after primary hepatectomy in patients with intrahepatic cholangiocarcinoma
verfasst von
Kazunori Tokuda
Yuji Morine
Yu Saito
Shinichiro Yamada
Katsuki Miyazaki
Shoko Yamashita
Shohei Okikawa
Tetsuya Ikemoto
Satoru Imura
Mitsuo Shimada
Publikationsdatum
31.08.2020
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 12/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-020-01775-x

Weitere Artikel der Ausgabe 12/2020

International Journal of Clinical Oncology 12/2020 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.